Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact

Isin US1510201049
Ticker CELG
Currency $
Aware Investor Index (AII) 0.0574
Recommendation SELL
P/E 122.30
ROE 13.93 %
Capitalization 100,835,776,000 $
Dividend Yield 0.00 %
P/S 10.89
AII Position 531
P/E Position 733
ROE Position 278
Capitalization Position 82
Dividend Yield Position 629
Sales 9,256,000,000 $
10-Year Average Earnings 824,515,000 $
Shares Outstanding 824,900,000
Equity 5,919,000,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
CELGENE Investor Relations Web Site http://ir.celgene.com


2015 12 9,256,000,000.00 $
2014 12 7,670,400,000.00 $
2013 12 6,493,900,000.00 $


2015 12 1,602,000,000.00 $
2014 12 1,999,900,000.00 $
2013 12 1,449,900,000.00 $
2012 12 1,456,180,000.00 $
2011 12 1,318,150,000.00 $
2010 12 880,512,000.00 $
2009 12 776,747,000.00 $
2008 12 -1,533,653,000.00 $
2007 12 226,433,000.00 $
2006 12 68,981,000.00 $


2015 12 5,919,000,000.00 $
2014 12 6,524,800,000.00 $
2013 12 5,589,900,000.00 $
2012 12 5,694,467,000.00 $
2011 12 5,512,727,000.00 $

Shares Outstanding:

2015 12 824,900,000
2014 12 836,000,000
2013 12 430,300,000
2012 12 440,796,000
2011 12 422,987,284


Bloomberg News for CELGENE:

Feb 21, 2018
Sell Side Says Chill Out on Alarming Yield Talk: Taking Stock
GD, HON, MMM, UTX and a bunch of railsHealthcare: RBC hosts an event with names such as CAH, CELG, DVAX (also awaiting update from CDC on Heplisav-B today), GILD, INCY, JNJ, RVNCEnergy: EnerCom...
Oct 26, 2017
Is Celgene's Fortune Running Out? Wall Street Looks for Answers
thing in the press release is that CELG has now taken down its 2020 guidance. The net decrease of $1 billion in 2020 numbers is due to lower expectations for CELG’s Oncology and I&I franchises offset...
Aug 4, 2010
Arbitrage Profit in U.S. Takeovers Pending on Aug. 4
08/25/10 ARG US APD US 63.50 65.30 -1.80 -2.76 77,416 Cash 08/13/10 ABII US CELG US 72.75 75.78 -3.03 -3.99 2,776 C&S 12/31/10 CASY US ATD/B CN 36.75 ...
Feb 10, 2012
Nasdaq Short Interest as of Jan. 31
642 5,536 CECE CECO ENVIRONMNTL 6,147 7,504 31,975 CELG CELGENE CORP 7,920,994 9,159,230 3,595,048 CELGZ CELGENE CORP-CVR...
Jan 21, 2011
S&P 500 Stocks With Biggest Gap Between Market Price, Estimate
15.30 19.39 -8.43 BAC BANK OF AMERICA 26.4 23 14.34 18.13 -11.57 CELG CELGENE CORP 26.2 22 56.37 71.14 -2.40 GME GAMESTOP CORP-A 25...
Jan 7, 2011
S&P 500 Stocks With Biggest Gap Between Market Price, Estimate
46.18 55.88 -2.48 JPM JPMORGAN CHASE 20.8 22 43.28 52.30 1.77 CELG CELGENE CORP 20.8 22 59.34 71.68 4.61 CSCO CISCO SYSTEMS 20...
Jan 13, 2010
North and South American Stock Rating Changes, New Coverage
-------------------------------------------------------------------------------- Celgene Corp (CELG US) EVA Dimensions Analyst Recommendation Action Target Team Coverage ...
May 16, 2008
Cancer Research Group Releases Data
meeting will be for additional uses for already approved drugs. Clinical trials of Celgene's (CELG) Revlimid, Bayer (BAYG.DE) and Onyx Pharmaceutical's (ONXX) Nexavar, Novartis' (NVS) Zometa, and...
Feb 7, 2005
Online Extra: Healthy Investment?
7.81 Abbott Laboratories (ABT) 7.51 Celgene (CELG) 7.15 Bristol-Myers Squibb (BMY) ...
Oct 14, 2005
Merrill Lynch Ups Celgene To Buy from Neutral
Merrill Lynch upgraded Celgene (CELG ) to buy from neutral, citing the stock's valuation. ...

Google News for CELGENE:

Seeking Alpha - 2 days ago
Celgene's (CELG) Management Presents at Barclays Global ...
Welcome to the afternoon sessions of the Barclays Global Healthcare Conference. My name is Geoff Meachem, I'm the Senior Biopharma Analyst here at Barclays. And it's our pleasure to have Celgene. And speaking on behalf of Celgene is CFO, Peter Kellogg and then Jonathan Biller from Tax and ...
Investorplace.com - 5 days ago
Celgene (CELG) a Strong Sell at $91.56
Celgene (CELG) a Strong Sell this week based on the most recent stock market rankings, and comparative pricing of its shares. Celgene Corp's (NASDAQ:CELG) Strong Sell recommendation, which was recently downgraded from a Sell to Strong Sell, is a result of a process of analysis that is proprietary ...
Seeking Alpha - 4 days ago
Updating Our Thoughts On Celgene
The combination of disruptive new discoveries coupled with burgeoning demand thanks to the aging demographics of the world's population sets the biotech space for a potential virtuous long-term cycle. That said, we're not too happy about the recent developments at Celgene. Let's talk about where the ...
Macon Daily - 7 hours ago
BidaskClub Lowers Celgene (CELG) to Strong Sell
BidaskClub downgraded shares of Celgene (NASDAQ:CELG) from a sell rating to a strong sell rating in a report published on Thursday. A number of other equities analysts have also recently weighed in on the company. Robert W. Baird reissued a hold rating and issued a $92.00 price target on shares of ...
Seeking Alpha - 5 Mar 2018
Why Celgene Is A Buy
It went from bad to worse for Celgene (CELG) this week as its shares dropped below $90 after the company was issued a Refusal to File letter by the FDA relating to a New Drug Application (NDA) for one of its most promising pipeline candidate, Ozanimod. The last six months have been full of setbacks for ...
Celgene (CELG) Receiving Somewhat Positive Media Coverage ...
Celgene logo Press coverage about Celgene (NASDAQ:CELG) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of ...
Frisco Fastball
This week, Celgene (CELG) a Strong Sell
At $89.04, Celgene (CELG) a Strong Sell based on the most recent relative pricing of its shares and market intelligence. Celgene Corp (NASDAQ:CELG), which was recently downgraded from a Sell, recommendation derives some benefit from being a component in a sector that is ranked near average in ...
Motley Fool
Celgene (CELG) Down 8.4% Since Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Celgene Corporation CELG. Shares have lost about 8.4% in that time frame, underperforming the market. Will the recent negative trend continue leading up to its next earnings release, or is CELG due for a breakout? Before we dive into how investors ...
Macon Daily - 1 day ago
Key Implications Of Celgene's Latest Fiasco (Ozanimod)
CELG sank 8% after hours Tuesday after disclosing that FDA rejected its NDA for ozanimod, its important MS candidate. This is just one more irritant for shareholders in this stock. Several inferences that I draw from this disappointment and the CELG story comprise the bulk of this article. A side note is that I ...
BZ Weekly
Celgene: Parsing The Ozanimod Debacle
Celgene Corporation [NASDAQ: CELG] today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ozanimod in development for the treatment of patients with relapsing forms of multiple sclerosis.